Cowen Remains Bullish Following Alexion Pharma's (ALXN) 3Q
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/23/2026
Go back to Cowen Remains Bullish Following Alexion Pharma's (ALXN) 3Q
October 29, 2015 7:52 AM EDT
Alexion Pharma (NASDAQ: ALXN) reported Q3 EPS of $1.16, $0.15 better than the analyst estimate of $1.01. Revenue for the quarter came in at $666.6 million versus the consensus estimate of $668.33 million.
Alexion Pharma sees FY2015 EPS of $4.92-$4.97, versus the consensus of $4.82.
The third... More
October 28, 2015 2:53 PM EDT
(Updated - October 28, 2015 2:54 PM EDT)
The Trading Radar highlights key earnings and economic announcements for the next trading session:
Before Markets Open:
Economics:
8:30am EDT
Initial Claims - Street sees 264kContinuing Claims - Street sees 2.185MGDP: Adv. - Street sees 1.6%Chain Deflator: Adv. - Street sees 1.3%
Earnings:
A.H. Belo (NYSE: AHC) - no Street consensus
Aetna (NYSE: AET) - consensus EPS $1.77
Air Products (NYSE: APD) -... More
October 27, 2015 9:14 AM EDT
Baird reiterated an Outperform rating and $221.00 price target on Alexion Pharmaceuticals (NASDAQ: ALXN) following Strensiq's FDA approval for hypophosphatasia. The company plans to use a sales force approximately double that at Soliris launch, to promote both Strensiq and Kanuma (PDUFA: December 8) along with Medical... More
